Please assess the completion status of the following clinical trial:

Trial Title: AryoTrust® (Trastuzumab) Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with HER2-positive breast cancer undergoing adjuvant chemotherapy regimens~Exclusion Criteria:~* Patients who had received Trastuzumab as part of their therapy or were not candidates for treatment continuation after adjuvant chemotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AryoGen Pharmed Trastuzumab (Type: None): AryoTrust is given at dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).